Fibrinogen heterogeneity in cancer, in occlusive vascular disease, and after surgical procedures.
Electrophoresis in 3.5% polyacrylamide gel was used to determine the patterns of fibrinogen heterogeneity in healthy subjects, in postoperative patients and in patients with cancer or occlusive vascular disease. Two major and one minor fibrinogen fractions, differing in molecular weight, were identified, and their concentrations in blood determined. The high-molecular-weight (HWM) fraction was found in greatest concentration after operation, during the period of hyperfibrinogenemia, whereas no simultaneous increase of lower-molecular-weight (LMW and LMW') fractions occurred, suggesting that these were derivatives of HMW ("native") fibrinogen. No correlation between the concentrations of the LMW and LMW' fractions and fibrinolytic activity was found, suggesting that direct degradation of HMW fibrinogen by plasmin was unlikely. The high fibrinogen level in cancer patients was related to increased concentrations of HMW and LMW fractions, whereas in the vascular-disease patients it was due exclusively to increased concentrations of LMW and LMW' fibrinogen. Serial observations indicated little fluctuation in the concentration of these fractions, indicating a persistently accelerated rate of conversion of HMW to LMW and LMW' fibrinogen in occlusive vascular disease. Possible pathogenic implications are discussed.
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000097:blood*; D001797:Blood Protein Electrophoresis; D003720:Densitometry; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen / Q000032:analysis*; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D009369:Neoplasms / Q000097:blood*; D013514:Surgical Procedures, Operative
D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen